This site is intended for Healthcare Professionals outside the US

Dose titration based on safety and efficacy considerations is important to optimise patient response to therapy1,2

JAKAVI dosing may be adjusted during therapy based on changes in platelet count and response1

Dose adjustments during treatment by platelet count1

Dose adjustments during JAK2 therapy for Myelofibrosis by platelet count - JAKAVI

Recommended dose adjustments based on response1:

  • The starting dose of JAKAVI should not be increased within the first 4 weeks of treatment and, thereafter, no more frequently than at 2-week intervals
  • If efficacy is considered insufficient and platelet and neutrophil counts are adequate, the JAKAVI dose may be increased by a maximum of 5 mg twice daily

Dose titration is a critical component of optimal patient management

Continuing therapy with JAKAVI1

  • Treatment may be continued as long as benefit-risk balance remains positive
  • Following interruption or discontinuation of JAKAVI, symptoms of myelofibrosis may return over a period of approximately 1 week*
  • Unless abrupt discontinuation is required, gradual tapering of the dose may be considered

Next: JAK dysregulation in myelofibrosis

*There have been cases of patients who sustained more severe events during discontinuation.


  1. JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; May 2019.
  2. Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol. 2013;6(79): doi:10.1186/1756-8722-6-79.